PDF(Pubmed)
Abstract：
UNASSIGNED: Antibiotics and albumin infusion constitute the standard of treatment in patients with decompensated cirrhosis who have spontaneous bacterial peritonitis (SBP). Recent studies have also shown that the use of albumin in patients with advanced liver disease who have infections other than SBP leads to the resolution of acute and chronic liver failure and prevents the development of nosocomial infections. The recommended dose of albumin for these patients is out of reach for many in resource-limited settings like India. The evidence for this recommendation is also scarce. This study aimed to assess the efficacy of a lower dose of albumin infusion in addition to antibiotics on short-term mortality and morbidity in patients with cirrhosis and infections.
UNASSIGNED: A prospective, open-label, randomized control study was performed. Consecutive patients with cirrhosis and infections were randomized in a 2:1 ratio into two groups: group A (116) and group B (58) patients. In addition to antibiotics and standard medical therapy, group A was given albumin in a dose of 20 g/day for five days, and group B was given the recommended dose (1.5 g/kg/body weight and 1 g/kg body weight on days one and three, respectively). The primary outcome was in-hospital mortality. Secondary outcomes were improvements in clinical and laboratory parameters.
UNASSIGNED: Except for etiology, all the baseline clinical and laboratory variables in both groups were comparable. The in-hospital mortality in groups A and B was (11 [10.67%] vs. 6 [10.09%], (P = 0.965). The duration of hospitalization, 30-day mortality, improvement in shock and sensorium, and absolute improvements in serum creatinine, international normalized ratio (INR), and serum bilirubin were also comparable in both groups.
UNASSIGNED: Low-dose albumin infusion in patients with cirrhosis and infections can have the same results as standard-dose albumin and can be used in resource-limited situations.
UNASSIGNED: CTRI/2020/03/023794.
UNASSIGNED: A prospective, open-label, randomized control study was performed. Consecutive patients with cirrhosis and infections were randomized in a 2:1 ratio into two groups: group A (116) and group B (58) patients. In addition to antibiotics and standard medical therapy, group A was given albumin in a dose of 20 g/day for five days, and group B was given the recommended dose (1.5 g/kg/body weight and 1 g/kg body weight on days one and three, respectively). The primary outcome was in-hospital mortality. Secondary outcomes were improvements in clinical and laboratory parameters.
UNASSIGNED: Except for etiology, all the baseline clinical and laboratory variables in both groups were comparable. The in-hospital mortality in groups A and B was (11 [10.67%] vs. 6 [10.09%], (P = 0.965). The duration of hospitalization, 30-day mortality, improvement in shock and sensorium, and absolute improvements in serum creatinine, international normalized ratio (INR), and serum bilirubin were also comparable in both groups.
UNASSIGNED: Low-dose albumin infusion in patients with cirrhosis and infections can have the same results as standard-dose albumin and can be used in resource-limited situations.
UNASSIGNED: CTRI/2020/03/023794.
摘要：
■抗生素和白蛋白输注构成了患有自发性细菌性腹膜炎（SBP）的失代偿性肝硬化患者的治疗标准。最近的研究还表明，在患有SBP以外的感染的晚期肝病患者中使用白蛋白可导致急性和慢性肝衰竭的解决，并防止医院感染的发展。对于像印度这样的资源有限的环境中的许多人来说，这些患者的白蛋白推荐剂量是遥不可及的。这一建议的证据也很少。本研究旨在评估除抗生素外，低剂量白蛋白输注对肝硬化和感染患者短期死亡率和发病率的疗效。
■预期，开放标签，进行随机对照研究.连续肝硬化和感染患者以2：1的比例随机分为两组：A组（116）和B组（58）患者。除了抗生素和标准的药物治疗,A组给予白蛋白，剂量为20克/天，持续五天，B组给予推荐剂量（在第1天和第3天给予1.5g/kg体重和1g/kg体重，分别)。主要结果是院内死亡率。次要结果是临床和实验室参数的改善。
■除了病因，两组的所有基线临床和实验室变量均具有可比性.A组和B组的住院死亡率为（11[10.67％]vs.6[10.09%]，(P=0.965)。住院时间,30天死亡率，改善休克和感觉，和血清肌酐的绝对改善，国际标准化比率(INR)，两组的血清胆红素水平也相当。
■肝硬化和感染患者的低剂量白蛋白输注可具有与标准剂量白蛋白相同的结果，可用于资源有限的情况。
■CTRI/2020/03/023794。
■预期，开放标签，进行随机对照研究.连续肝硬化和感染患者以2：1的比例随机分为两组：A组（116）和B组（58）患者。除了抗生素和标准的药物治疗,A组给予白蛋白，剂量为20克/天，持续五天，B组给予推荐剂量（在第1天和第3天给予1.5g/kg体重和1g/kg体重，分别)。主要结果是院内死亡率。次要结果是临床和实验室参数的改善。
■除了病因，两组的所有基线临床和实验室变量均具有可比性.A组和B组的住院死亡率为（11[10.67％]vs.6[10.09%]，(P=0.965)。住院时间,30天死亡率，改善休克和感觉，和血清肌酐的绝对改善，国际标准化比率(INR)，两组的血清胆红素水平也相当。
■肝硬化和感染患者的低剂量白蛋白输注可具有与标准剂量白蛋白相同的结果，可用于资源有限的情况。
■CTRI/2020/03/023794。
